Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 351

1.

LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.

Morishima T, Krahl AC, Nasri M, Xu Y, Aghaallaei N, Findik B, Klimiankou M, Ritter M, Hartmann MD, Gloeckner CJ, Stefańczyk S, Lindner C, Oswald B, Bernhard R, Hähnel K, Hermanutz-Klein U, Ebinger M, Handgretinger R, Casadei N, Welte K, Andre M, Müller P, Bajoghli B, Skokowa J.

Blood. 2019 Jul 31. pii: blood.2019000095. doi: 10.1182/blood.2019000095. [Epub ahead of print]

PMID:
31366618
2.

CRISPR/Cas9 mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients.

Nasri M, Ritter M, Mir P, Dannenmann B, Aghaallaei N, Amend D, Makaryan V, Xu Y, Fletcher B, Bernhard R, Steiert I, Hahnel K, Berger J, Koch I, Sailer B, Hipp K, Zeidler C, Klimiankou M, Bajoghli B, Dale DC, Welte K, Skokowa J.

Haematologica. 2019 Jun 27. pii: haematol.2019.221804. doi: 10.3324/haematol.2019.221804. [Epub ahead of print]

3.

Ultra-Sensitive CSF3R Deep Sequencing in Patients With Severe Congenital Neutropenia.

Klimiankou M, Uenalan M, Kandabarau S, Nustede R, Steiert I, Mellor-Heineke S, Zeidler C, Skokowa J, Welte K.

Front Immunol. 2019 Feb 28;10:116. doi: 10.3389/fimmu.2019.00116. eCollection 2019.

4.

Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response.

Nasri M, Mir P, Dannenmann B, Amend D, Skroblyn T, Xu Y, Schulze-Osthoff K, Klimiankou M, Welte K, Skokowa J.

Blood Adv. 2019 Jan 8;3(1):63-71. doi: 10.1182/bloodadvances.2017015511.

5.

Human iPSC-based model of severe congenital neutropenia reveals elevated UPR and DNA damage in CD34+ cells preceding leukemic transformation.

Dannenmann B, Zahabi A, Mir P, Oswald B, Bernhard R, Klimiankou M, Morishima T, Schulze-Osthoff K, Zeidler C, Kanz L, Lachmann N, Moritz T, Welte K, Skokowa J.

Exp Hematol. 2019 Mar;71:51-60. doi: 10.1016/j.exphem.2018.12.006. Epub 2019 Jan 4.

PMID:
30615903
6.

Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.

Dale DC, Bolyard AA, Marrero T, Kelley ML, Makaryan V, Tran E, Leung J, Boxer LA, Kishnani PS, Austin S, Wanner C, Ferrecchia IA, Khalaf D, Maze D, Kurtzberg J, Zeidler C, Welte K, Weinstein DA.

Curr Opin Hematol. 2019 Jan;26(1):16-21. doi: 10.1097/MOH.0000000000000474.

PMID:
30451720
7.

NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils.

Pylaeva E, Harati MD, Spyra I, Bordbari S, Strachan S, Thakur BK, Höing B, Franklin C, Skokowa J, Welte K, Schadendorf D, Bankfalvi A, Brandau S, Lang S, Jablonska J.

Int J Cancer. 2019 Jan 1;144(1):136-149. doi: 10.1002/ijc.31808. Epub 2018 Oct 30.

PMID:
30121947
8.

The new diagnostic team.

Graber ML, Rusz D, Jones ML, Farm-Franks D, Jones B, Cyr Gluck J, Thomas DB, Gleason KT, Welte K, Abfalter J, Dotseth M, Westerhaus K, Smathers J, Adams G, Laposata M, Nabatchi T, Compton M, Eichbaum Q.

Diagnosis (Berl). 2017 Nov 27;4(4):225-238. doi: 10.1515/dx-2017-0022.

PMID:
29536943
9.

Gene correction of HAX1 reversed Kostmann disease phenotype in patient-specific induced pluripotent stem cells.

Pittermann E, Lachmann N, MacLean G, Emmrich S, Ackermann M, Göhring G, Schlegelberger B, Welte K, Schambach A, Heckl D, Orkin SH, Cantz T, Klusmann JH.

Blood Adv. 2017 Jun 2;1(14):903-914. doi: 10.1182/bloodadvances.2016003798. eCollection 2017 Jun 13.

10.

Severe congenital neutropenias.

Skokowa J, Dale DC, Touw IP, Zeidler C, Welte K.

Nat Rev Dis Primers. 2017 Jun 8;3:17032. doi: 10.1038/nrdp.2017.32. Review.

11.

GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signaling.

Koch C, Samareh B, Morishima T, Mir P, Kanz L, Zeidler C, Skokowa J, Welte K.

Ann Hematol. 2017 Mar;96(3):345-353. doi: 10.1007/s00277-016-2894-5. Epub 2016 Dec 14.

PMID:
27966038
12.

Thrombopoietin induces hematopoiesis from mouse ES cells via HIF-1α-dependent activation of a BMP4 autoregulatory loop.

Pramono A, Zahabi A, Morishima T, Lan D, Welte K, Skokowa J.

Ann N Y Acad Sci. 2016 Jul;1375(1):38-51. doi: 10.1111/nyas.13138.

PMID:
27447537
13.

Role of CSF3R mutations in the pathomechanism of congenital neutropenia and secondary acute myeloid leukemia.

Klimiankou M, Mellor-Heineke S, Zeidler C, Welte K, Skokowa J.

Ann N Y Acad Sci. 2016 Apr;1370(1):119-25. doi: 10.1111/nyas.13097.

PMID:
27270496
14.

Two cases of cyclic neutropenia with acquired CSF3R mutations, with 1 developing AML.

Klimiankou M, Mellor-Heineke S, Klimenkova O, Reinel E, Uenalan M, Kandabarau S, Skokowa J, Welte K, Zeidler C.

Blood. 2016 May 26;127(21):2638-41. doi: 10.1182/blood-2015-12-685784. Epub 2016 Mar 30. No abstract available.

15.

Leukemogenic potency of the novel FLT3-N676K mutant.

Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z.

Ann Hematol. 2016 Apr;95(5):783-91. doi: 10.1007/s00277-016-2616-z. Epub 2016 Feb 19.

PMID:
26891877
16.

ELANE mutant-specific activation of different UPR pathways in congenital neutropenia.

Nustede R, Klimiankou M, Klimenkova O, Kuznetsova I, Zeidler C, Welte K, Skokowa J.

Br J Haematol. 2016 Jan;172(2):219-27. doi: 10.1111/bjh.13823. Epub 2015 Nov 16.

PMID:
26567890
17.

GM-CSF stimulates granulopoiesis in a congenital neutropenia patient with loss-of-function biallelic heterozygous CSF3R mutations.

Klimiankou M, Klimenkova O, Uenalan M, Zeidler A, Mellor-Heineke S, Kandabarau S, Skokowa J, Zeidler C, Welte K.

Blood. 2015 Oct 8;126(15):1865-7. doi: 10.1182/blood-2015-07-661264. Epub 2015 Aug 31. No abstract available.

18.

[Germline mutations in children with cancer - leopoldina meeting report, september 26, 2014, jesuit monastery merzhausen].

Borkhardt A, Welte K, Olschewski E, Niemeyer C.

Klin Padiatr. 2014 Nov;226(6-7):382-4. doi: 10.1055/s-0034-1394422. Epub 2014 Nov 28. German.

PMID:
25431872
19.

The diversity of mutations and clinical outcomes for ELANE-associated neutropenia.

Makaryan V, Zeidler C, Bolyard AA, Skokowa J, Rodger E, Kelley ML, Boxer LA, Bonilla MA, Newburger PE, Shimamura A, Zhu B, Rosenberg PS, Link DC, Welte K, Dale DC.

Curr Opin Hematol. 2015 Jan;22(1):3-11. doi: 10.1097/MOH.0000000000000105. Review.

20.

JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia.

Boztug K, Järvinen PM, Salzer E, Racek T, Mönch S, Garncarz W, Gertz EM, Schäffer AA, Antonopoulos A, Haslam SM, Schieck L, Puchałka J, Diestelhorst J, Appaswamy G, Lescoeur B, Giambruno R, Bigenzahn JW, Elling U, Pfeifer D, Conde CD, Albert MH, Welte K, Brandes G, Sherkat R, van der Werff Ten Bosch J, Rezaei N, Etzioni A, Bellanné-Chantelot C, Superti-Furga G, Penninger JM, Bennett KL, von Blume J, Dell A, Donadieu J, Klein C.

Nat Genet. 2014 Sep;46(9):1021-7. doi: 10.1038/ng.3069. Epub 2014 Aug 17.

21.

Outcome and management of pregnancies in severe chronic neutropenia patients by the European Branch of the Severe Chronic Neutropenia International Registry.

Zeidler C, Grote UA, Nickel A, Brand B, Carlsson G, Cortesão E, Dufour C, Duhem C, Notheis G, Papadaki HA, Tamary H, Tjønnfjord GE, Tucci F, Van Droogenbroeck J, Vermylen C, Voglova J, Xicoy B, Welte K.

Haematologica. 2014 Aug;99(8):1395-402. doi: 10.3324/haematol.2013.099101. Epub 2014 Jul 4.

22.

TCIRG1-associated congenital neutropenia.

Makaryan V, Rosenthal EA, Bolyard AA, Kelley ML, Below JE, Bamshad MJ, Bofferding KM, Smith JD, Buckingham K, Boxer LA, Skokowa J, Welte K, Nickerson DA, Jarvik GP, Dale DC; UW Center for Mendelian Genomics.

Hum Mutat. 2014 Jul;35(7):824-7. doi: 10.1002/humu.22563. Epub 2014 May 21.

23.

Double-stranded DNA in exosomes: a novel biomarker in cancer detection.

Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, Zheng Y, Hoshino A, Brazier H, Xiang J, Williams C, Rodriguez-Barrueco R, Silva JM, Zhang W, Hearn S, Elemento O, Paknejad N, Manova-Todorova K, Welte K, Bromberg J, Peinado H, Lyden D.

Cell Res. 2014 Jun;24(6):766-9. doi: 10.1038/cr.2014.44. Epub 2014 Apr 8. No abstract available.

24.

G-CSF: filgrastim, lenograstim and biosimilars.

Welte K.

Expert Opin Biol Ther. 2014 Jul;14(7):983-93. doi: 10.1517/14712598.2014.905537. Epub 2014 Apr 7. Review.

PMID:
24707817
25.

Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis.

Skokowa J, Steinemann D, Katsman-Kuipers JE, Zeidler C, Klimenkova O, Klimiankou M, Unalan M, Kandabarau S, Makaryan V, Beekman R, Behrens K, Stocking C, Obenauer J, Schnittger S, Kohlmann A, Valkhof MG, Hoogenboezem R, Göhring G, Reinhardt D, Schlegelberger B, Stanulla M, Vandenberghe P, Donadieu J, Zwaan CM, Touw IP, van den Heuvel-Eibrink MM, Dale DC, Welte K.

Blood. 2014 Apr 3;123(14):2229-37. doi: 10.1182/blood-2013-11-538025. Epub 2014 Feb 12.

26.

Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34(+) cells.

Gupta K, Kuznetsova I, Klimenkova O, Klimiankou M, Meyer J, Moore MA, Zeidler C, Welte K, Skokowa J.

Blood. 2014 Apr 17;123(16):2550-61. doi: 10.1182/blood-2012-09-456889. Epub 2014 Jan 6.

27.

A lack of secretory leukocyte protease inhibitor (SLPI) causes defects in granulocytic differentiation.

Klimenkova O, Ellerbeck W, Klimiankou M, Ünalan M, Kandabarau S, Gigina A, Hussein K, Zeidler C, Welte K, Skokowa J.

Blood. 2014 Feb 20;123(8):1239-49. doi: 10.1182/blood-2013-06-508887. Epub 2013 Dec 18.

28.

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy.

Stankov MV, El Khatib M, Kumar Thakur B, Heitmann K, Panayotova-Dimitrova D, Schoening J, Bourquin JP, Schweitzer N, Leverkus M, Welte K, Reinhardt D, Li Z, Orkin SH, Behrens GM, Klusmann JH.

Leukemia. 2014 Mar;28(3):577-88. doi: 10.1038/leu.2013.264. Epub 2013 Sep 12.

29.

High-content cytometry and transcriptomic biomarker profiling of human B-cell activation.

Hennig C, Ilginus C, Boztug K, Skokowa J, Marodi L, Szaflarska A, Sass M, Pignata C, Kilic SS, Caragol I, Baumann U, Klein C, Welte K, Hansen G.

J Allergy Clin Immunol. 2014 Jan;133(1):172-80.e1-10. doi: 10.1016/j.jaci.2013.06.047. Epub 2013 Sep 5. Erratum in: J Allergy Clin Immunol. 2014 Apr;133(4):1232.

PMID:
24012209
30.

Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000.

Schrappe M, Möricke A, Reiter A, Henze G, Welte K, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Gruhn B, Niemeyer C, Kremens B, Niggli F, Debatin KM, Ratei R, Stanulla M, Beier R, Cario G, Schrauder A, Zimmermann M.

Klin Padiatr. 2013 May;225 Suppl 1:S62-72. doi: 10.1055/s-0033-1337966. Epub 2013 May 22.

PMID:
23700060
31.

[Research in pediatric hematology [Germany, 1970-2000]].

Welte K.

Klin Padiatr. 2013 May;225 Suppl 1:S45-9. doi: 10.1055/s-0033-1337963. Epub 2013 May 22. German.

PMID:
23700055
32.

[The West-Berlin therapy study of acute lymphoblastic leukemia in childhood--report after 6 years].

Riehm H, Gadner H, Welte K.

Klin Padiatr. 2013 May;225 Suppl 1:S16-29. doi: 10.1055/s-0033-1337959. Epub 2013 May 22. German.

PMID:
23700050
33.

Defective G-CSFR signaling pathways in congenital neutropenia.

Skokowa J, Welte K.

Hematol Oncol Clin North Am. 2013 Feb;27(1):75-88, viii. doi: 10.1016/j.hoc.2012.11.001. Epub 2012 Nov 27. Review.

PMID:
23351989
34.

Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis.

Skokowa J, Klimiankou M, Klimenkova O, Lan D, Gupta K, Hussein K, Carrizosa E, Kusnetsova I, Li Z, Sustmann C, Ganser A, Zeidler C, Kreipe HH, Burkhardt J, Grosschedl R, Welte K.

Nat Med. 2012 Oct;18(10):1550-9. doi: 10.1038/nm.2958. Epub 2012 Sep 23.

35.

Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells.

Thakur BK, Dittrich T, Chandra P, Becker A, Kuehnau W, Klusmann JH, Reinhardt D, Welte K.

Int J Cancer. 2013 Feb 15;132(4):766-74. doi: 10.1002/ijc.27726. Epub 2012 Aug 12.

36.

Inhibition of SIRT1 by HIV-1 viral protein Tat results in activation of p53 pathway.

Thakur BK, Chandra A, Dittrich T, Welte K, Chandra P.

Biochem Biophys Res Commun. 2012 Jul 27;424(2):245-50. doi: 10.1016/j.bbrc.2012.06.084. Epub 2012 Jun 23.

PMID:
22732402
37.

Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells.

Thakur BK, Dittrich T, Chandra P, Becker A, Lippka Y, Selvakumar D, Klusmann JH, Reinhardt D, Welte K.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):371-7. doi: 10.1016/j.bbrc.2012.06.075. Epub 2012 Jun 21.

PMID:
22728882
38.

NAMPT pathway is involved in the FOXO3a-mediated regulation of GADD45A expression.

Thakur BK, Lippka Y, Dittrich T, Chandra P, Skokowa J, Welte K.

Biochem Biophys Res Commun. 2012 Apr 20;420(4):714-20. doi: 10.1016/j.bbrc.2012.03.017. Epub 2012 Mar 10.

PMID:
22430142
39.

The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells.

Dan L, Klimenkova O, Klimiankou M, Klusman JH, van den Heuvel-Eibrink MM, Reinhardt D, Welte K, Skokowa J.

Haematologica. 2012 Apr;97(4):551-9. doi: 10.3324/haematol.2011.055236. Epub 2011 Dec 29.

40.

Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome.

Zeidler L, Zimmermann M, Möricke A, Meissner B, Bartels D, Tschan C, Schrauder A, Cario G, Goudeva L, Jäger S, Ratei R, Ludwig WD, Teigler-Schlegel A, Skokowa J, Koehler R, Bartram CR, Riehm H, Schrappe M, Welte K, Stanulla M.

Haematologica. 2012 Mar;97(3):402-9. doi: 10.3324/haematol.2011.045229. Epub 2011 Nov 4.

41.

Extended spectrum of human glucose-6-phosphatase catalytic subunit 3 deficiency: novel genotypes and phenotypic variability in severe congenital neutropenia.

Boztug K, Rosenberg PS, Dorda M, Banka S, Moulton T, Curtin J, Rezaei N, Corns J, Innis JW, Avci Z, Tran HC, Pellier I, Pierani P, Fruge R, Parvaneh N, Mamishi S, Mody R, Darbyshire P, Motwani J, Murray J, Buchanan GR, Newman WG, Alter BP, Boxer LA, Donadieu J, Welte K, Klein C.

J Pediatr. 2012 Apr;160(4):679-683.e2. doi: 10.1016/j.jpeds.2011.09.019. Epub 2011 Nov 1.

PMID:
22050868
42.

Awareness and acceptance of public cord blood banking among practicing obstetricians in the United States.

Walker T, Steckler D, Spellman S, Haven D, Welte K, Boo M.

Transfusion. 2012 Apr;52(4):787-93. doi: 10.1111/j.1537-2995.2011.03383.x. Epub 2011 Oct 7.

PMID:
21981791
43.

Family-directed umbilical cord blood banking.

Gluckman E, Ruggeri A, Rocha V, Baudoux E, Boo M, Kurtzberg J, Welte K, Navarrete C, van Walraven SM; Eurocord, Netcord, World Marrow Donor Association and National Marrow Donor Program.

Haematologica. 2011 Nov;96(11):1700-7. doi: 10.3324/haematol.2011.047050. Epub 2011 Jul 12. Review.

44.

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.

Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grümayer R, Möricke A, Parasole R, Zimmermann M, Dworzak M, Buldini B, Reiter A, Basso G, Klingebiel T, Messina C, Ratei R, Cazzaniga G, Koehler R, Locatelli F, Schäfer BW, Aricò M, Welte K, van Dongen JJ, Gadner H, Biondi A, Conter V.

Blood. 2011 Aug 25;118(8):2077-84. doi: 10.1182/blood-2011-03-338707. Epub 2011 Jun 30.

45.

Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.

Hartmann C, Weinel P, Schmid H, Grigull L, Sander A, Linderkamp C, Welte K, Reinhardt D.

J Pediatr Hematol Oncol. 2011 Jul;33(5):344-9. doi: 10.1097/MPH.0b013e31820994ec.

PMID:
21572345
46.

ICSBP promoter methylation in myelodysplastic syndromes and acute myeloid leukaemia.

Otto N, Manukjan G, Göhring G, Hofmann W, Scherer R, Luna JC, Lehmann U, Ganser A, Welte K, Schlegelberger B, Steinemann D.

Leukemia. 2011 Jul;25(7):1202-7. doi: 10.1038/leu.2011.61. Epub 2011 Apr 8. No abstract available.

PMID:
21475251
47.

PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.

Koestner W, Hapke M, Herbst J, Klein C, Welte K, Fruehauf J, Flatley A, Vignali DA, Hardtke-Wolenski M, Jaeckel E, Blazar BR, Sauer MG.

Blood. 2011 Jan 20;117(3):1030-41. doi: 10.1182/blood-2010-04-283119. Epub 2010 Nov 9.

48.

Cyclic and chronic neutropenia.

Dale DC, Welte K.

Cancer Treat Res. 2011;157:97-108. doi: 10.1007/978-1-4419-7073-2_6. Review.

PMID:
21052952
49.

Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy.

Rosenberg PS, Zeidler C, Bolyard AA, Alter BP, Bonilla MA, Boxer LA, Dror Y, Kinsey S, Link DC, Newburger PE, Shimamura A, Welte K, Dale DC.

Br J Haematol. 2010 Jul;150(2):196-9. doi: 10.1111/j.1365-2141.2010.08216.x. Epub 2010 Apr 29.

50.

Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse.

Ehlers S, Herbst C, Zimmermann M, Scharn N, Germeshausen M, von Neuhoff N, Zwaan CM, Reinhardt K, Hollink IH, Klusmann JH, Lehrnbecher T, Roettgers S, Stary J, Dworzak M, Welte K, Creutzig U, Reinhardt D.

J Clin Oncol. 2010 May 20;28(15):2591-7. doi: 10.1200/JCO.2009.25.9010. Epub 2010 Apr 20.

PMID:
20406937

Supplemental Content

Support Center